Aims: Benefits of long acting beta 2 agonists are unclear for severe chronic obstructive pulmonary disease (COPD) patients with poor response to short acting bronchodilators. We aimed to evaluate 1) effects of eformoterol in such patients using a 'n-of-l' double crossover study design, and 2) aggregate data as a double-blind, double crossover randomized control trial. Methods: Subjects with forced expiratory volume in one second (FEV1) < 60% predicted, and poor response to short acting bronchodilators were studied six times over 18 weeks. During that time they were prescribed four weeks of either eformoterol or placebo, followed by the alternate, and then a second crossover. Fourweekly measures included six minute walk distance (6MWD), FEVI, previous two weeks of symptoms, and chronic respiratory questionnaire (CRQ) including treatment goal items. Results: Of 27 original subjects (21 male, mean age of 70 years, five smokers, mean prebronchodilator FEV, 36% predicted), one subject had clinically significant concordant improvement in the CRQ dyspnoea domain and 6MWD (by 51 metres), but not for other outcomes. There were no concordant improvements in any other subjects. Aggregate double crossover data analysis demonstrated no improvement in any outcome measures. Conclusions: The 'n-of-' study design and aggregate data analysis demonstrated lack of benefit from eformoterol in COPD patients with poor response to short acting bronchodilators.
Introduction
Chronic obstructive pulmonary disease (COPD) is a condition characterized by expiratory airflow obstruction, which is not fully reversible. COPD is associated with frequent hospital admissions,' high direct and indirect health care costs2 and is Australia's fourth leading cause of death.3 It is a devastating disease, such that when severe, some people rate their quality of life as being on par with paraplegia and AIDS. COPD also places a substantial burden upon carers.5 Short acting beta 2 adrenoreceptor agonists (SABA) are used widely for symptom relief in the management of patients with both asthma and COPD. Long acting beta 2 adreno-receptor agonists (LABA) have clearly been shown to improve symptoms in patients with asthma and to act as steroid sparing agents, but their place in the management of COPD patients who have a poor response to SABA is less certain.
Our systematic review6 of relevant randomized control trials with salmeterol7-1 1 as well as more recently reported trials using eformoterol,12,13 demonstrate small benefits in measures of airflow in all studies, no improvement in six minute walk distance (6MWD),7'8'1213 no reduction in exacerbations,8 and inconsistent changes in health-related quality of life (HRQL).11 15 'N-of-i 'studies were successfully demonstrated over a decade ago to facilitate management decisions in COPD.16 However, despite the therapeutic and cost saving merits of such an approach, n-of-I trials have not been widely taken up in clinical practice. We therefore aimed to use an n-of-I double crossover design15 in a series of individual patients with COPD who had little reversibility to SABA, in order to evaluate the effect of long term eformoterol upon a primary outcome of HRQL, including activity items tailored to each subject's own treatment goals.17 Secondary outcomes included objective measures of change in lung function. In order to present and discuss an overview of this series of n-of-I subjects, and to draw inferences about overall likelihood of benefit in this specific patient group, we also aimed to qualitatively and quantitatively aggregate all subjects' data, and use repeated measures analysis. Such a value added approach to n-of-I trials may encourage greater endorsement of such trials in clinical practice, while retaining individual feedback both to patients and their clinicians.
Methods
Ethics approval was obtained by the Ethics of Human Research Committee at the North Westem Adelaide Health Service. There were 43 subjects recruited from respiratory clinics primarily dealing with asthma and COPD in hospital and private practice settings. Inclusion criteria required that subjects were aged between 40 and 80 years, were current smokers or exsmokers, experienced at least mild shortness ofbreath on exertion, had a baseline FEV, of < 60% of predicted value and FEVI/forced vital capacity (FVC) ratio <60%, were stable at time of entry into the study (no deteriorations requiring emergency hospital or local medical officer visits or hospital admissions in the previous 28 days), and had poorly reversible airways obstruction defined by the British Thoracic Society (an increase in FEV, of not greater than 15% and 200 mL after salbutamoll'). No attempt was made in our recruitment to distinguish between emphysema and chronic bronchitis. Patients were excluded from entry into the trial if they had a history of asthma by their clinician, unstable airways disease, other respiratory disease, other uncontrolled disease, had changes in their medication in the previous 28 days, or were on beta blocker medication.
Study design
Each subject underwent an n-of-I trial.19 Visit 1 was followed by a two-week run in phase to familiarize participants with the protocol. Subjects returned to the clinic for follow up assessment to receive their first medication (Visit 2), and were then seen a further four times at four-weekly intervals (Visits 3-6) in a double crossover manner. For each study period, each subject received either 24 jig eformoterol twice a day or placebo twice a day, making a total trial duration of 18
Chronic Respiratory Disease weeks. The randomization code for eformoterol and placebo turbuhalers was independently supplied in opaque envelopes, with allocation on study entry in order to blind subjects, research staff, and two respiratory physicians who inspected the outcome data for each individual participant.
Subjects underwent an initial assessment including a medical history, examination, spirometry by Sensor-Medics 6200 Autobox pre-and post-salbutamol including withholding of rescue medication at least six hours prior to testing, six-minute walk distance (6MWD) test, and provision of a diary for recording symptoms, reliever use and prednisolone booster courses (Visit 1). All pulmonary function testing was performed in a Thoracic Society of Australia and New Zealand accredited laboratory, according to American Thoracic Society standards.20 The eformoterol or placebo was continued until the morning of the tests of each four week visit before crossing over to the new medication. Measures were repeated at each visit.
The Chronic Respiratory Disease Questionnaire (CRQ)15 is divided into four domains (dyspnoea, fatigue, emotion and mastery), and was administered at each study visit. In the dyspnoea domain, the subject nominates five important activities of daily living which are treatment goals but which are currently limited due to shortness of breath. The instrument is therefore suitable for n-of-I evaluations. Threshold for a clinically relevant change is 0.5 units/item per domain.17
Subjects used the symptom diary during the run in phase and only in the last two weeks of each of the four treatment periods, in order to avoid any carryover effect of the previous (placebo or eformoterol) period. Daytime symptoms were recorded on a six point scale ranging from zero (no symptoms) to five (symptoms so severe that daily activities could not be performed), and night-time symptoms on a five point scale ranging from zero (no symptoms) to four (symptoms so severe that subjects could not sleep at all) according to previously reported methods.9
Aggregate data analysis Baseline measures were estimated as the average of the first two visits. The double crossover trial was run and analysed as a ABBA/BAAB (A = eformoterol and B = placebo) dual balanced design with delay in measures to minimize carryover effects between treatment periods. This is considered one of the most efficient designs for a two treatment, four period trial under the assumption of simple carryover and independent erro.21 Data were analysed using repeated measures ANCOVA, including treatment, period and carryover effects with baseline measure as a 222 covariate2 in STATA version 6.23
Results
Of 43 subjects who agreed to participate, 27 were eligible and commenced the trials with 22 subjects completing their double crossover n-of-I trials. Reasons for exclusion were ineligibility at first visit (n = 16: comprising 10 persons with FEV, reversibility of greater than 200 mL and 15% of prebronchodilator FEV1, five persons with >60% predicted FEV1, and one person with confusion/dementia). Five subjects withdrew during the trials, two due to personal reasons and three subjects withdrew due to problems related to other medical conditions. Of these, three withdrew prior to randomization at Visit 2, and one subject each prior to visits four and five. Symptom diary completion was well performed with the exception of one participant.
The baseline measures of the 27 subjects averaged across Visit 1 and 2 (either side of the run in period) are shown in Table 1 . Symptoms scores recorded in the diary prior to the second visit were used as baseline. The mean post bronchodilator FEV1 reversibility in this patient group was 12.1% of baseline values indicating that this group was poorly responsive to SABA.24 CRQ scores for Visit 1 and Visit 2 were highly correlated by Kendall's tau; all P-values < 0.05. n-of-i trials Eformoterol was not associated with clinically significant consistent improvements across outcome measures in any subjects based upon blinded comparison of average outcome scores for the end of the two placebo periods against the two eformoterol periods, by two physicians. Nor did the two physicians note any differences in any of the outcomes after the two placebo periods or the two eformoterol periods. This is consistent with the reported validity and reproducibility of the measures used, including the CRQ. 15 One subject with a significant improvement in the CRQ dyspnoea domain also improved his 6MWD by 51 metres while on eformoterol (from 328 to 379 metres), but lacked improvements in any other outcome measures. While most subjects experienced no significant HRQL change, some patients experienced inconsistent benefits and some subjects' HRQL worsened. Figure 1 shows the difference between eformoterol and placebo in relation to the mean ofthe two CRQ scores obtained at the end of each of the eformoterol and placebo periods, at the level of the minimal clinically significant difference of 0.5 units per item.17 Of the 22 subjects completing the double crossover, two subjects experienced significant improvements in the four CRQ domains, and two subjects demonstrated significant improvements in two of the four domains. Additionally, one subject significantly worsened while on eformoterol in all four CRQ domains, and two subjects worsened in three domains of the CRQ. Differences between mean scores for eformoterol and placebo periods in relation to other outcome measures for subjects are summarized in Figure 2 . Differences between placebo and eformoterol were under 2% of predicted for both presalbutamol and postsalbutamol scores, however reversibility associated with salbutamol was almost 10% greater with the placebo period. Use of prednisolone booster courses was not significantly different between the eformoterol and placebo periods (15 and 17 respectively) in the 22 subjects who completed the trials. Overall in this patient group, eformoterol did not improve quality of life, as measured by CRQ, or 6MWD. There was no significant reduction in salbutamol use, or the number of day and night time COPD symptoms experienced during the eformoterol and placebo treatment periods. Figure 2 The eformoterol treatment-placebo difference for individual subjects' symptom score, FEVI, six minute walk distance (6MWD). 
Pooled analysis

Discussion
Recently, LABA have been recommended as a first choice treatment option over anticholinergic and SABA therapy for stable COPD.25 However, subjects with reversible obstructive airways disease (ROAD) have a heterogeneous response to LABA. 26 In our 22 completed n-of-I trials of eformoterol in severe COPD patients who had poor reversibility to SABA, we found a lack of benefit when outcomes were assessed on a patient by patient basis. Although one patient had improvement in dyspnoea according to CRQ and a concordant increase in 6MWD, there was a lack of other outcome benefits. The ongoing use of LABA in this patient may be justifiable. There were also improvements in two subjects in day time symptoms, while no subjects noted worsening day time symptoms. However both of these two subjects' improvements were not associated with concordant improvements in other outcomes, and all 20 other subjects had no change in daytime symptoms. It is possible that 6MWD has limited value in our elderly subjects due to comorbidities such as osteoarthritis. However, of those subjects with a change in 6MWD, most favoured placebo. We chose the CRQ as a disease specific outcome, as it includes five patient specified activities against which exertional dyspnoea can be measured. This instrument is well validated and shown to have acceptable reproducibility.15
Patients were encouraged to identify those activities of importance to them individually as treatment goals, that dyspnoea was currently making difficult. Despite this level of individualization, there was a lack of improvement in most subjects. Compliance was not evaluated in our study, and post hoc efficacy analysis not performed, as the n-of-I design is suited to an intention to treat approach.
Analysis of aggregate data also demonstrated a lack of benefit in terms of FEV1, exercise tolerance, COPD symptoms, rescue bronchodilator usage, or the domains of quality of life including exertional dyspnoea. We chose FEV1 over peak expiratory flow rate as our principal measure of airflow limitation as it is less effort dependent, which is important in elderly frail subjects with COPD. We did find attenuated reversibility to SABA and reduced use of salbutamol after eformoterol treatment periods, indicating a small degree of bronchodilation had occurred when the patients were taking eformoterol. In the setting of patients who have continued access to SABA the addition of formoterol was not associated with any improvements in other outcomes, including quality of life and symptoms. Our study lacked power to perform post hoc subgroup analysis.
Our Cochrane review of long term salmeterol in people with COPD who have poor reversibility to SABA6 summarized small improvements in FEV1 of the order of 100 mL but a lack of improvements in a range of other objective and subjective outcome measures. Eformoterol has different properties to salmeterol, and requires separate consideration. A study of eformoterol in elderly subjects with COPD, who did have a reversible component of airflow obstruction27 (mean FEV1 reversibility after SABA of 0.3L) demonstrated no differences between treatment groups in FEV1 after three months of treatment.
A study of eformoterol in COPD by Stahl et al.12 found small improvements in FEVy and symptom scores, but not in quality of life (as measured by St George's Respiratory Questionnaire), nor in 6MWD. However, the magnitude of change of 109 mL in the subgroup of subjects with poor reversibility to SABA, as in the study by Rossi et al. 13 is of uncertain clinical significance, as HRQL was not reported in this subgroup. FEV, change has been demonstrated to be a poor marker of health status response to therapy28 and may not change when dyspnoea and exercise tolerance do improve. 29 Recently, a large RCT30 was conducted to determine the efficacy of three doses of eformoterol in 690 subjects with mild to severe non reversible COPD. The study found that while there were no significant differences between any dose of eformo-terol and placebo in terms of distance walked during the shuttle walking test compared to placebo, significant improvements were demonstrated for the 9 and 18 pLg doses in terms of symptom free days and FEV1 significantly increased after all doses of eformoterol. The lack of benefit demonstrated in most of our n-of-I subjects, according to either individual data or aggregate data analysis, may relate to differing reversibility exclusion criteria, as well as our selection of HRQL as our primary outcome.
Although conducting n-of-I trials requires a considerable commitment of doctor and patient time, the savings to be made from restricting the use of long term eformoterol and other LABA to patients for whom they can be shown to be beneficial are great. Our study was of subjects with severe COPD, without reversibility to SABA on the basis of a single test. Additional evidence of asthma based upon eosinophilia was not sought because a history of asthma was an exclusion criteria and furthermore such testing is not considered to be routine clinical practise in COPD management. We have not assessed the efficacy of long term LABA in patients with COPD who have some degree of reversibility so it is not appropriate to generalize our findings to encompass these people. Also, due to the design of this study, titration of the dose of LABA was not possible so we do not know if higher doses may be effective.
Our double crossover design enabled a powerful study with a relatively small sample size. In lieu of a formal power calculation which has not been reported for this type of study, we were guided by a previously reported study of the effects of salmeterol7 using a single crossover design, with a similar sample size to ours (n = 29, 24 completed). This study had sufficient power to detect outcome measure improvements considered clinically relevant in COPD. Therefore it is unlikely that a lack of power explains our findings, particularly given that we used a double crossover design with repeated measures analysis, with subjects acting as their own control. While it remains possible that a larger study may have detected small improvements the number of subjects needed to treat for a benefit to one subject would also become greater, reducing cost effectiveness. It is also unlikely that ineffective drug delivery explains the findings as a recent study has reported that subjects with COPD and severely limited lung function (FEV1 < 1 L) are able to generate sufficient inspiratory flow to operate a turbuhaler effectively.3 Although compliance was not formally assessed there is no reason to expect a differential compliance between active and placebo periods. Our intention was to design a trial that could mimic usual clinical practice. 68 Responsiveness to SABA forms a continuous distribution.32 Distinction between COPD and COPD with asthma is difficult33 and reproducibility of 'reversible' spirometry findings in COPD is poor. 34 Our study investigated the responsiveness of patients to LABA who had poor response to SABA. Given their lack of response to SABA we do not find it surprising they did not respond to LABA. Our findings in these poorly reversible COPD patients do not negate the possibility that some COPD patients who have a greater than 200 mL response to SABA may get some benefit from LABA.
We used individual n-of-I trials, with data aggregation, to study a subset of COPD patients with poor reversibility to SABA, according to reported criteria. 18 The inherent double crossover design of n-of-I trials also provided an opportunity for relatively powerful aggregate analysis without large sample size, as subjects act as their own controls, and the double crossover permits using repeated measures analysis. This design approach also enables trial participants to receive personalized feedback as to any benefits gained from the medication under evaluation. However, we found inconsistent and marginal benefits of eformoterol in this COPD subset.
